Fish oil omega-3 fatty acids and cardio-metabolic health, alone or with statins.
The impact of the fish-derived omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on cardiovascular disease (CVD) and type 2 diabetes incidence and risk has been widely investigated. Although the balance of evidence suggests substantial benefits with respect to CVD mortality, there is little evidence for an impact of these fatty acids on insulin sensitivity and diabetes incidence, despite very promising data from animal models. The focus here will be the plasma lipid modulatory effects of EPA and DHA and will include an exploration of the potential and demonstrated complementarity between statins and EPA/DHA on overall CVD risk and the plasma cholesterol and triglyceride profile. Although there is some justification for greater general population and patient EPA+DHA intakes, an often overlooked major obstacle is that global fish stocks are limited and insufficient to meet demands. The potential of emerging 'non-fish foods' to provide affordable and sustainable sources of EPA+DHA will also be briefly discussed.